Treatment for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
The University of Texas at Austin, Austin, TX
Obsessive-Compulsive Disorder+9 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question "can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?"

Eligible Conditions

  • Obsessive-Compulsive Disorder
  • Phobia, Social
  • Anxiety Disorders
  • Panic Attacks
  • Post Traumatic Stress Disorder (PTSD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: Weekly for 14 weeks + follow-up after 24 weeks

Week 13 (post-treatment)
Non-response to exposure-based therapy
Week 24
Clinical Global Impression (CGI)
Clinical Global Impression - Severity of Illness (CGI-S)
Dimensional Obsessive-Compulsive Scale (DOCS)
GAD-7
Overall Anxiety Severity and Impairment Scale (OASIS)
PTSD Checklist for DSM-5 (PCL-5)
Panic Disorder Severity Scale (PDSS)
Social Phobia Inventory (SPIN)

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

600 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: weekly for 14 weeks + follow-up after 24 weeks
Closest Location: The University of Texas at Austin · Austin, TX
Photo of Austin 1Photo of Austin 2Photo of Austin 3
2006First Recorded Clinical Trial
1 TrialsResearching Obsessive-Compulsive Disorder
24 CompletedClinical Trials

Who is running the clinical trial?

Boston UniversityOTHER
410 Previous Clinical Trials
10,023,144 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,489 Previous Clinical Trials
1,765,310 Total Patients Enrolled
59 Trials studying Obsessive-Compulsive Disorder
12,367 Patients Enrolled for Obsessive-Compulsive Disorder
University of Texas at AustinLead Sponsor
283 Previous Clinical Trials
66,641 Total Patients Enrolled
2 Trials studying Obsessive-Compulsive Disorder
161 Patients Enrolled for Obsessive-Compulsive Disorder
Jasper Smits, Ph.D.Principal InvestigatorThe University of Texas at Austin
3 Previous Clinical Trials
132 Total Patients Enrolled
Michael Otto, Ph.D.Principal InvestigatorBoston University

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a score of 8 or greater on the OASIS.
You are proficient in English.
You are willing and able to provide informed consent and comply with the requirements of the study protocol.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.